SinoMab BioScience Limited
HKEX:3681.HK
Overview | Financials
Company Name | SinoMab BioScience Limited |
Symbol | 3681.HK |
Currency | HKD |
Price | 1.07 |
Market Cap | 1,156,332,415 |
Dividend Yield | 0% |
52-week-range | 1 - 1.95 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Shui On Leung |
Website | https://www.sinomab.com |
An error occurred while fetching data.
About SinoMab BioScience Limited
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA),
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD